Comparison of seven immunoassays for the quantification of CA 125 antigen in serum

Clinical Chemistry

Volumn 44, Issue 7, 1998, Pages 1417-1422

  Davelaar, Elvira M ^a   Van Kamp, Gerard J ^a   Verstraeten, Rob A ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; PELVIS TUMOR; QUANTITATIVE DIAGNOSIS; RELIABILITY;

EID: 0031804389     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.7.1417     Document Type: Article

References (16)

1. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
2. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology-a review. Eur J Obstet Gynecol Reprod Biol 1993;49:115-24.
3. Yedema CA, Kenemans P, Voorhorst FG, Bon GG, Schii̧f CPT, Beex LVAM, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993;67:1361-7.
4. van Kamp GJ, Verstraeten AA, Kenemans P. Discordant serum CA 125 values in commercial immunoassays. Eur J Obstet Gynecol and Reprod Biol 1993;49:99-103.
5. Kenemans P. Bon GG, Kessler AC, Verstraeten AA, van Kamp GJ. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clin Chem 1992;38:1466-71.
6. Kenemans P, van Kamp GJ, Oehr P, Verstraeten AA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993;39:2509-13.
7. Uhl W, Denk B. Improved CA 125 determinations using two different monoclonal antibodies. In: Klapdor R, ed. Current tumor diagnosis: applications, clinical relevance, research, trends. Munich: Zuckschwerdt Verlag, 1994:384-8.
8. Kenemans P, Verstraeten AA, van Kamp GJ, von Mensdorff-Pouilly S. The second generation CA 125 assays. Ann Med 1995;27: 107-13.
9. Bonfrèr JMG, Baan AW, Jansen E, Lentfer D. Kenemans P. Technical evaluation of three second generation CA 125 assays. Eur J Clin Chem Clin Biochem 1994;32:201-7.
10. Nustad K, Bast RC Jr, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. Tumor Biol 1996;17:196-219.
11. Schutter EMJ, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, et al. Diagnostic value of pelvic mass examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. Cancer 1994;74:1398-1406.
12. Yedema CA, Massuger L, Hilgers J, Servaas J, Poels L, Thomas CMG, et al. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA 125 and CA 15.3 serum assays, Int J Cancer 1988;3(Suppl):61-7.
13. Yedema CA, Kenemans P. Wobbes T, Thomas CMG, Bon GG, Mulder C, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumor Biol 1992;13:18-26.
14. Davelaar EM, Bonfrèr JMG, Verstraeten AA, ten Bokkel Huinink WW, Kenemans P. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer 1996;78:1:118-27.
15. Hompes PGA, Koninckx PR, Kennedy S, van Kamp GJ, Verstraeten AA, Cornillie F. Serum CA 125 concentrations during midfollicular phase, a clinically useful and reproducible marker in diagnosis of advanced endometriosis. Clin Chem 1996;42:1871-4.
16. Özaksit G, Çaǧlar T, Çiçek N, Kuşçu E, Batioǧlu S, Gökmen O. Serum CA 125 levels before, during and after treatment for endometriosis. Int J Gynecol Obstet 1995;50:269-73.